About Obsidio
Obsidio is a company based in Solana Beach (United States) founded in 2018 by Ali Khademhosseini, Rahmi Oklu, and Ehsan Jabbarzadeh was acquired by Boston Scientific in August 2022. Obsidio has raised $3 million across 4 funding rounds from investors including Boston Scientific, Good Growth Capital and National Heart, Lung, and Blood Institute. Obsidio operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
- Headquarter Solana Beach, United States
- Founders Ali Khademhosseini, Rahmi Oklu, Ehsan Jabbarzadeh
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website obsidiomed.com
- Social LinkedIn X
- Acquired by Boston Scientific (Aug 2022)
- Total Equity Funding$3M (USD)
in 4 rounds
- Latest Funding Round$2.1M (USD), Grant
Jul 2021
- InvestorsBoston Scientific
& 4 more
- Acquired byBoston Scientific
(Aug 2022)
Funding Insights of Obsidio
Obsidio has successfully raised a total of $3M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $2.1 million completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3M
- Total Rounds 4
- Last Round Grant — $2.1M
- Investors Count 4
All 4 funding rounds of Obsidio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2021 | $2.1M | Grant | – | – | |
| Aug 2020 | $3M | Seed | – | IAG Capital Partners | |
| Aug 2020 | $225,000 | Grant | – | – | |
| Aug 2019 | – | Seed | – | Good Growth Capital | – |
5 investors in total: 5 institutional.
Investors in Obsidio
Obsidio has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Boston Scientific, Good Growth Capital and National Heart, Lung, and Blood Institute.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are provided by IAG Capital Partners. | – | iagcapitalpartners.com | Charleston, USA | |
Early-stage investments are made in life sciences and technologies. | 2017 | goodgrowthvc.com | Charleston, United States | |
Venture capital fund backed by the US Government | – | seedfund.nsf.gov | Alexandria, United States | |
Research on heart, lung, blood, and sleep disorders is conducted. | – | nhlbi.nih.gov | Bethesda, United States | |
Wide range of medical devices | 1979 | bostonscientific.com | Marlborough, United States |
Investor details for Obsidio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Obsidio
31 people are tracked at Obsidio (17 in leadership, 10 in board & advisors, 4 in team).
| Name | Role | Group |
|---|---|---|
Ali Khademhosseini | Founder | Leadership |
Rahmi Oklu | Founder | Leadership |
Ehsan Jabbarzadeh | Founder & CEO | Leadership |
Jeff Mirviss | EVP & President, Peripheral Interventions | Leadership |
Scott Olson | SVP & President, Cardiac Rhythm Management & Diagnostics | Leadership |
Joseph M. Fitzgerald | EVP & Group President, Cardiology | Leadership |
Daniel J. Brennan | EVP & CFO | Leadership |
Stephen Morse | SVP & President, Asia Pacific | Leadership |
Mary Beth Moynihan | SVP, Market Access & Chief Marketing Officer | Leadership |
Lance Bates | SVP & President, Interventional Cardiology Therapies | Leadership |
Jodi Eddy | SVP, Chief Information & Digital Officer | Leadership |
Meghan Scanlon | SVP & President, Urology and Pelvic Health | Leadership |
Michael Jones | SVP & President, Endoscopy | Leadership |
Arthur C. Butcher | EVP & Group President, MedSurg & Asia Pacific | Leadership |
Michael F. Mahoney | Chairman & CEO | Leadership |
Eric Thépaut | EVP & President, Europe, Middle East & Africa | Leadership |
Kenneth Stein | Senior Vice President & Global Chief Medical Officer | Leadership |
Jessica L. Mega | Board Member | Board & advisors |
Susan E. Morano | Board Member | Board & advisors |
Charles J. Dockendorff | Board Member | Board & advisors |
11 more people are available in the full profile.
Complete people profiles for Obsidio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Obsidio
4 dated milestones of Obsidio across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Obsidio is founded.
- Funding First funding round.
- Funding Latest funding round, Grant, of $2.1M.
- Exit Acquired by Boston Scientific.
Competitors of Obsidio
Obsidio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| straumann.com | 1954 | Basel, Switzerland | – | – | Dental implants and regenerative dentistry products are developed. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| judges.uk.com | 2002 | London, United Kingdom | – | 622 | Acquisition and development of scientific instrument businesses is conducted. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. |
Detailed competitors of Obsidio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Obsidio
Complete news archive for Obsidio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Obsidio
10 companies that operate in the same segment as Obsidio (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Obsidio
Obsidio was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Obsidio is headquartered in Solana Beach, United States. It is registered at Solana Beach, California, United States.
Ehsan Jabbarzadeh is the current CEO of Obsidio. They have also founded this company.
Obsidio is a funded company, having raised a total of $3M across 4 funding rounds to date.
Obsidio was founded in 2018 in Solana Beach, United States, within the medical technology sector focused on biomaterials. A shear-thinning biomaterial technology is being advanced for minimally invasive delivery of a polymer via catheter to stop blood flow. The material is designed to thin under pressure for injection and solidify upon pressure release, enabling applications such as hemorrhage control, tumor vessel occlusion, arteriovenous malformation prevention, and aneurysm treatment.
Obsidio's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Obsidio has 5 investors. Key investors include Boston Scientific, Good Growth Capital, National Heart, Lung, and Blood Institute, IAG Capital Partners, and America’s Seed Fund.
Yes. Obsidio was acquired by Boston Scientific in August 2022.